Seroconversion after Recombinant Hepatitis B Vaccination


  • Abhijit Guho Lecturer, Department of Microbiology, Khulna Medical College
  • Md abdul Ahad Associate Professor, Department of Gastroenterology, Khulna Medical College
  • Md Abdus Salam Assistant Professor, Department of Microbiology, Rajshahi Medical College
  • Md Abdul Alim Associate Professor, Department of Gastroenterology, Rajshahi Medical College
  • AKM Enamul Haque Lecturer, Department of Community Medicine, Rajshahi Medical College
  • Quazi Tarikul Islam Professor, Department of Medicine, Dhaka Medical College



Hepatitis B, hepatitis B vaccine, seroconversion, Bangladesh


Background: Hepatitis B virus infection is an important public health problem with significant morbidity and
mortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in different
parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in
EPI schedule since 2005.
Materials and methods: This study was carried out to assess the seroconversion status among hepatitis B
vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently
healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-
EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All
individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and
only HBsAg-negative persons were included for estimation of their anti-HBs titer.
Results: Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level
(>10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated
controls had anti-HBs titers below the protective level. Regarding immune response developed among vaccinated
individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively.
Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who
received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose.
Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found
in 85.88% male and 92.31% female individuals. There was no significant difference of anti-HBs titer between male
and female (p>0.05). Vaccinated individuals from lower socioeconomic condition have had comparatively low rate
of protective antibody than people from middle and upper classes.
Conclusion: Recombinant HB vaccine induces good level of protective immunity among vaccinated persons.

Keywords: Hepatitis B; hepatitis B vaccine; seroconversion; Bangladesh

DOI: 10.3329/jom.v11i2.5461

J MEDICINE 2010; 11 : 143-150


Download data is not yet available.


How to Cite

Guho, A., Ahad, M. abdul, Salam, M. A., Alim, M. A., Haque, A. E., & Islam, Q. T. (2010). Seroconversion after Recombinant Hepatitis B Vaccination. Journal of Medicine, 11(2), 143–150.



Original Articles